Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Emma Bernsen

PhD student
Emma Bernsen
Emma Bernsen
Pharmacology and Pharmacogenomics in Pediatric Oncology

Our research is focused on two main topics: pharmacogenomics and pharmacokinetic (PK) / pharmacodynamics (PD) modeling. We are studying the role of genetic variants in treatment response and susceptibility to toxicity in pediatric oncology. Also, we want to integrate genetic variants in PK/PD models of classical chemotherapy as well as novel treatments (e.g. immunotherapy) to study their effect on pharmacokinetics and pharmacodynamics in children. With our research we hope to contribute to precision medicine and be able to deliver personalized therapies to children with cancer.

Knowledge & experience

  • Pharmacology
  • Pharmacogenomics
  • Pharmacokinetic/pharmacodynamic modeling

Working experience

2012-2019       Pharmacy BSc/MSc (Utrecht University)

2019-2021       Pharmacist, Princess Máxima Center for Pediatric Oncology

2021-present   PhD Candidate Huitema Group


LinkedIn: https://www.linkedin.com/in/emma-bernsen-05824a82/
ORCID: https://orcid.org/0000-0002-0249-1216

  • Ernstig acute nierschade na high-dose methotrexaat bij een patiënt met polymorfismen in ABCB1 en ABCBG2

    • mrt. 2023
    • Emma, Bernsen, et al
    • Nederlands Tijdschrift voor Oncologie (NTvO)
  • Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity

    • jan. 2023
    • E C, Bernsen, et al
    • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • Practical Recommendations for the Manipulation of Kinase Inhibitor Formulations to Age-Appropriate Dosage Forms

    • dec. 2022
    • Emma C, Bernsen, et al
    • Pharmaceutics
  • Practical recommendations for the manipulation of kinase inhibitor formulations to suitable pediatric dosage forms

    • dec. 2022
    • Emma, Bernsen, et al
    • Pharmaceutics
  • Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics

    • aug. 2020
    • Emma C., Bernsen, et al
    • Frontiers in Pharmacology
View all publications